Becker's Healthcare December 4, 2024
A new phase 3 clinical trial found that Eli Lilly’s weight loss drug Zepbound resulted in significantly greater weight loss than Wegovy.
Over a 72-week period, patients taking Zepbound lost an average of 20.2% of their body weight, compared to 13.7% for those taking Wegovy, according to a Dec. 4 Eli Lilly news release.
The trial studied adults who were either obese or overweight and had at least one weight-related health issue, excluding diabetes. Zepbound outperformed Wegovy on both the primary endpoint and all five secondary endpoints. Notably, 31.6% of Zepbound users achieved 25% weight loss, with only 16.1% of those using Wegovy reaching that milestone.
Both drugs belong to a class of...
Today's Sponsors
Today's Sponsor